Volume 28, Number 1—January 2022
Dispatch
SARS-CoV-2 RNA Shedding in Semen and Oligozoospermia of Patient with Severe Coronavirus Disease 11 Weeks after Infection
Table 2
RT-PCR and serologic test results for participant 1 who was infected with SARS-CoV-2 in longitudinal prospective coronavirus disease cohort study, New York, USA*
Days after symptom onset | Sample | PCR result, Ct | Binding antibody EC50, NP/S | Neutralizing antibody IC50 | T cell reactivity against M protein, IFN-γ‒secreting T cells/million PBMCs† |
---|---|---|---|---|---|
72 | Saliva | Negative | |||
72 |
Blood |
Negative |
1,351/3,728 (modest) |
(modest) |
|
78 |
Saliva |
Negative |
|||
78 |
Stool |
Negative |
|||
78 |
Blood |
Negative |
1,756/5,680 (modest) |
(modest) |
|
81 |
Semen |
Positive, 34.79 |
|||
81 |
Blood |
NT |
>130 (strong) |
||
81 |
Saliva |
Negative |
|||
101 |
Semen |
Negative |
|||
101 |
Saliva |
Negative |
|||
101 |
Stool |
Negative |
|||
169 |
Saliva |
Negative |
|||
169 | Stool | Negative | |||
169 | Semen | Negative |
*Ct, cycle threshold; EC50, concentration half of the maximum effect; IC50, half-maximal inhibitory concentration; IFN, interferon; NP, nucleocapsid protein; NT, not tested; PBMCs, peripheral blood mononuclear cells; S, spike protein; SARS-CoV 2, severe acute respiratory syndrome coronavirus 2.
Page created: October 01, 2021
Page updated: December 20, 2021
Page reviewed: December 20, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.